Ha habido 50 transacciones internas recientes registradas para Femasys Inc. (FEMY), incluyendo 40 compras y 1 venta. El total de compras internas fue valorado en $1.52M y el total de ventas internas en $6.25M.
Internos destacados con actividad reciente incluyen Canning John Charles, Elefant Dov, Lee-sepsick Kathy. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — FEMY
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2026-03-30 |
Canning John Charles |
Chief Operating Officer |
Desconocido |
- |
- |
- |
30,000 |
| 2026-03-30 |
Canning John Charles |
Chief Operating Officer |
Concesión de RSU |
150,000 |
$0.38 |
$57K |
150,000 |
| 2026-03-19 |
Elefant Dov |
Chief Financial Officer |
Concesión de RSU |
34,122 |
$0.58 |
$19.79K |
34,122 |
| 2026-03-19 |
Lee-sepsick Kathy |
Chief Executive Officer |
Concesión de RSU |
68,244 |
$0.58 |
$39.58K |
68,244 |
| 2026-03-19 |
Larsen Charles |
Director |
Concesión de RSU |
34,122 |
$0.58 |
$19.79K |
34,122 |
| 2026-03-19 |
Eichenbaum Kenneth D. |
Director |
Concesión de RSU |
102,366 |
$0.58 |
$59.37K |
102,366 |
| 2026-03-18 |
Eichenbaum Kenneth D. |
Director |
Concesión de RSU |
35,200 |
$0.60 |
$21.12K |
35,200 |
| 2026-03-18 |
Eichenbaum Kenneth D. |
Director |
Desconocido |
- |
- |
- |
25,010 |
| 2026-03-17 |
Pharmacyte Biotech, Inc. |
10 Percent Owner |
Desconocido |
- |
- |
- |
- |
| 2026-03-17 |
Silverman Joshua |
Director |
Desconocido |
- |
- |
- |
- |
| 2026-02-19 |
Elefant Dov |
Chief Financial Officer |
Concesión de RSU |
169,000 |
- |
- |
169,000 |
| 2026-02-19 |
Lee-sepsick Kathy |
Chief Executive Officer |
Concesión de RSU |
282,000 |
- |
- |
282,000 |
| 2026-02-02 |
Sipos Jeremy Alexander |
Chief Technology Officer |
Concesión de RSU |
80,000 |
- |
- |
80,000 |
| 2025-12-16 |
Sipos Jeremy Alexander |
Chief Technology Officer |
Desconocido |
3,334 |
$6.12 |
$20.4K |
- |
| 2025-11-07 |
Elefant Dov |
Chief Financial Officer |
Compra Discrecional |
- |
$0.73 |
- |
- |
| 2025-11-07 |
Larsen Charles |
Director |
Compra Discrecional |
- |
$0.73 |
- |
- |
| 2025-11-07 |
Lee-sepsick Kathy |
Chief Executive Officer |
Compra Discrecional |
- |
$0.73 |
- |
- |
| 2025-11-07 |
Eichenbaum Kenneth D. |
Director |
Desconocido |
102,366 |
$1.10 |
$112.6K |
- |
| 2025-08-27 |
Elefant Dov |
Chief Financial Officer |
Compra Discrecional |
38,828 |
$0.52 |
$20K |
38,828 |
| 2025-08-27 |
Lee-sepsick Kathy |
Chief Executive Officer |
Compra Discrecional |
48,535 |
$0.52 |
$25K |
48,535 |
| 2025-06-25 |
Silverman Joshua |
Director |
Concesión de RSU |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-25 |
Uzialko Edward R |
Director |
Concesión de RSU |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-25 |
Larsen Charles |
Director |
Concesión de RSU |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-25 |
Milnes Alistair |
Director |
Concesión de RSU |
17,600 |
$0.98 |
$17.25K |
17,600 |
| 2025-06-23 |
Nicholas Kelley Stinson |
Chief Commercial Officer |
Desconocido |
- |
- |
- |
45 |
| 2025-06-23 |
Nicholas Kelley Stinson |
Chief Commercial Officer |
Concesión de RSU |
100,000 |
$0.90 |
$90K |
100,000 |
| 2025-06-02 |
Elefant Dov |
Chief Financial Officer |
Compra Discrecional |
19,608 |
$1.02 |
$20K |
19,608 |
| 2025-06-02 |
Lee-sepsick Kathy |
Chief Executive Officer |
Compra Discrecional |
34,314 |
$1.02 |
$35K |
312,092 |
| 2025-06-02 |
Currie Daniel Scott |
Chief Operating Officer |
Compra Discrecional |
19,608 |
$1.02 |
$20K |
86,275 |
| 2025-06-02 |
Larsen Charles |
Director |
Compra Discrecional |
24,510 |
$1.02 |
$25K |
56 |
| 2025-01-29 |
Lee-sepsick Kathy |
Chief Executive Officer |
Concesión de RSU |
59,849 |
$1.17 |
$70.02K |
59,849 |
| 2025-01-28 |
Elefant Dov |
Chief Financial Officer |
Concesión de RSU |
72,045 |
$1.05 |
$75.65K |
72,045 |
| 2025-01-28 |
Currie Daniel Scott |
Chief Operating Officer |
Concesión de RSU |
29,184 |
$1.05 |
$30.64K |
29,184 |
| 2025-01-28 |
Thomas Christine E |
Chief Reg & Clinical Officer |
Concesión de RSU |
23,600 |
$1.05 |
$24.78K |
23,600 |
| 2024-07-12 |
Silverman Joshua |
Director |
Concesión de RSU |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-07-12 |
Uzialko Edward R |
Director |
Concesión de RSU |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-07-12 |
Larsen Charles |
Director |
Concesión de RSU |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-07-12 |
Milnes Alistair |
Director |
Concesión de RSU |
17,600 |
$1.14 |
$20.06K |
17,600 |
| 2024-02-12 |
Spector Richard D. |
Officer |
Desconocido |
- |
- |
- |
- |
| 2024-02-12 |
Spector Richard D. |
Chief Commercial Officer |
Concesión de RSU |
100,000 |
$1.10 |
$110K |
100,000 |
| 2024-02-01 |
Elefant Dov |
Chief Financial Officer |
Concesión de RSU |
84,000 |
$0.80 |
$67.2K |
84,000 |
| 2024-02-01 |
Lee-sepsick Kathy |
Chief Executive Officer |
Concesión de RSU |
204,900 |
$0.80 |
$163.92K |
204,900 |
| 2024-02-01 |
Currie Daniel Scott |
Chief Operating Officer |
Concesión de RSU |
61,900 |
$0.80 |
$49.52K |
61,900 |
| 2024-02-01 |
Thomas Christine E |
SVP, Regulatory & Clinical |
Concesión de RSU |
32,600 |
$0.80 |
$26.08K |
32,600 |
| 2023-11-21 |
Silverman Joshua |
Officer |
Desconocido |
- |
- |
- |
- |
| 2023-11-21 |
Silverman Joshua |
Director |
Concesión de RSU |
17,000 |
$0.90 |
$15.3K |
17,000 |
| 2023-11-21 |
Pharmacyte Biotech, Inc. |
10 Percent Owner |
Disposición |
4,237,288 |
$1.48 |
$6.25M |
- |
| 2023-10-10 |
Thomas Christine E |
SVP, Regulatory & Clinical |
Concesión de RSU |
60,000 |
$1.76 |
$105.6K |
60,000 |
| 2023-07-03 |
Elefant Dov |
Chief Financial Officer |
Concesión de RSU |
105,200 |
$0.49 |
$51.55K |
105,200 |
| 2023-07-03 |
Lee-sepsick Kathy |
Chief Executive Officer |
Concesión de RSU |
270,400 |
$0.49 |
$132.5K |
270,400 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
